Abstract: The invention relates to a composition containing catechins found in green tea, to pharmaceutical compositions and medical devices comprising the composition and to the use of these compositions and medical devices in the treatment of coronavirus infections, especially infection with SARS-CoV-2.

Abstract: Contemplated compositions and methods include a catechin at a concentration effective to inactivate SARS at least by a factor of 2 log 10 units when the formulation is applied to a surface. Preferably, the catechins are provided as a complex mixture, and most preferably as a near-native catechin preparation from green tea.

Abstract: Contemplated methods and compositions further increase susceptibility of sensitized MRSA against various antibiotic drugs. Most preferably, the MRSA is already sensitized with a galloylated catechin (e.g., ECG), and further sensitization is achieved by exposure to a non-galloylated catechin (e.g., EC), and most preferably the corresponding non-galloylated catechin.

Abstract: Compositions and methods are directed to covalent adducts between reducing agents and optionally substituted 3-hydroxyflavans, wherein the reducing agent is covalently bound to the B-ring of the 3-hydroxyflavan. Such adducts exhibit markedly increased stability towards oxidation as compared to the unmodified 3-hydroxyflavan. Particularly preferred 3-hydroxyflavans include green tea catechins, and especially EGCG, while especially preferred reducing agents include NAC and glutathione.

Abstract: Compositions and methods are directed to covalent adducts between reducing agents and optionally substituted 3-hydroxyflavans, wherein the reducing agent is covalently bound to the B-ring of the 3-hydroxyflavan. Such adducts exhibit markedly increased stability towards oxidation as compared to the unmodified 3-hydroxyflavan. Particularly preferred 3-hydroxyflavans include green tea catechins, and especially EGCG, while especially preferred reducing agents include NAC and glutathione.

Abstract: Contemplated compositions and methods utilize a combination of a polyphenol and a non-polyphenol cyclooxygenase-2 inhibitor. Preferably, the compositions are pharmaceutical and/or nutraceutical compositions and formulated in a dosage form and amount such that the polyphenol and the non-polyphenol cyclooxygenase-2 inhibitor are effective to reduce tumor incidence and/or multiplicity. In preferred aspects, the polyphenol is epigallocatechin gallate, epigallocatechin, epicatechin gallate, epicatechin, and/or a mixture of polyphenols isolated from a plant (e.g., polyphenon E), and the cyclooxygenase-2 inhibitor is rofecoxib, celecoxib, and/or valdecoxib.

Abstract: Topical compositions, and particularly hydrophobic compositions include an essential oil in an amount effective to achieve substantially complete absorption of the composition in the skin without leaving a greasy residue. Especially preferred topical compositions may also include pharmaceutically active agents (e.g., polyphenol), additional essential oils, stabilizers, etc. In further preferred aspects, contemplated compositions may delay onset, or even prevent viral eruptions on the skin, and where applied as a lipstick, will increase reddening of the lip as well as reduce chapping.

Abstract: The objective of the present invention is to provide a tea polyphenol composition that has reduced bitterness and astringency while containing catechins with high purity. The present invention provides a tea polyphenol composition, (A) comprising 85% by weight to 95% by weight of catechins, (B) wherein the catechins contains epigallocatechin gallate and gallocatechin gallate at a ratio of 65% by weight to 80% by weight and (C) wherein the ratio given by (epigallocatechin gallate+gallocatechin gallate)/(epicatechin+catechin+epigallocatechin+gallocatechin+epicatechin gallate+catechin gallate) is from 2 to 4.

Abstract: Compositions and methods are provided in which a topical hydrophilic formulation includes a catechin and a hydrophilic antioxidant in a hydrophilic composition at a ratio of between 2.3 to 1.7 (by weight), ad wherein the catechin and the antioxidant are present in an amount such that application of the composition to skin will deposit the catechin at a dosage of between 0.7 mg/cm2 and 1.3 mg/cm2. Especially preferred catechins include green tea catechins, and particularly EGCG, while preferred antioxidants include ascorbic acid and derivatives thereof.

Abstract: The objective of the present invention is to provide a tea polyphenol composition that has reduced bitterness and astringency while containing catechins with high purity. The present invention provides a tea polyphenol composition, (A) comprising 85% by weight to 95% by weight of catechins, (B) wherein the catechins contains epigallocatechin gallate and gallocatechin gallate at a ratio of 65% by weight to 80% by weight and (C) wherein the ratio given by (epigallocatechin gallate+gallocatechin gallate)/(epicatechin+catechin+epigallocatechin+gallocatechin+epicatechin gallate+catechin gallate) is from 2 to 4.

Abstract: Contemplated methods and compositions further increase susceptibility of sensitized MRSA against various antibiotic drugs. Most preferably, the MRSA is already sensitized with a galloylated catechin (e.g., ECG), and further sensitization is achieved by exposure to a non-galloylated catechin (e.g., EC), and most preferably the corresponding non-galloylated catechin.

Abstract: A catechin is modified in at least one position (most preferably in the 3-position of the C-ring) to increase its lipophilicity. Contemplated catechins are demonstrated to have significantly improved antibacterial properties, likely due to catastrophic membrane damage.

Abstract: Contemplated compositions and methods utilize a combination of a polyphenol and a non-polyphenol cyclooxygenase-2 inhibitor. Preferably, the compositions are pharmaceutical and/or nutraceutical compositions and formulated in a dosage form and amount such that the polyphenol and the non-polyphenol cyclooxygenase-2 inhibitor are effective to reduce tumor incidence and/or multiplicity. In preferred aspects, the polyphenol is epigallocatechin gallate, epigallocatechin, epicatechin gallate, epicatechin, and/or a mixture of polyphenols isolated from a plant (e.g., polyphenon E), and the cyclooxygenase-2 inhibitor is rofecoxib, celecoxib, and/or valdecoxib.

Abstract: Compositions and methods are directed to covalent adducts between reducing agents and optionally substituted 3-hydroxyflavans, wherein the reducing agent is covalently bound to the B-ring of the 3-hydroxyflavan. Such adducts exhibit markedly increased stability towards oxidation as compared to the unmodified 3-hydroxyflavan. Particularly preferred 3-hydroxyflavans include green tea catechins, and especially EGCG, while especially preferred reducing agents include NAC and glutathione.

Abstract: Contemplated compositions and methods include a catechin at a concentration effective to inactivate SARS at least by a factor of 2 log 10 units when the formulation is applied to a surface. Preferably, the catechins are provided as a complex mixture, and most preferably as a near-native catechin preparation from green tea.

Abstract: The objective of the present invention is to provide a tea polyphenol composition that has reduced bitterness and astringency while containing catechins with high purity. The present invention provides a tea polyphenol composition, (A) comprising 85% by weight to 95% by weight of catechins, (B) wherein the catechins contains epigallocatechin gallate and gallocatechin gallate at a ratio of 65% by weight to 80% by weight and (C) wherein the ratio given by (epigallocatechin gallate+gallocatechin gallate)/(epicatechin+catechin+epigallocatechin+gallocatechin+epicatechin gallate+catechin gallate) is from 2 to 4.

Abstract: A catechin is modified in at least one position (most preferably in the 3-position of the C-ring) to increase its lipophilicity. Contemplated catechins are demonstrated to have significantly improved antibacterial properties, likely due to catastrophic membrane damage.

Abstract: Bacterial vaginosis is treated using methods and compositions that include one or more plant polyphenols as active ingredients. Preferred routes of administration of contemplated plant polyphenols include topical and oral administration, and particularly preferred plant polyphenols are prepared from green tea (e.g., Polyphenon E) and/or may include (?)-epigallocatechin gallate, (?)-epicatechin gallate, (?)-epigallocatechin, and (?)-epicatechin.

Abstract: The present invention relates to an anti-Chlamydia agent characterized by containing tea polyphenol and to a method for preventing or treating a Chlamydia infectious disease, characterized by comprising administering a composition containing tea polyphenol in an amount effective for the therapy of a Chlamydia infectious disease on an affected part of a patient.

Abstract: A chewing gum which has a preventative effect against infection by influenza virus and inhibits dissemination of influenza virus. The chewing gum comprises adding at least 0.03 weight % of at least one tea polyphenol, for a chewing gum containing no organic acids; the chewing gum comprises at least 0.01 weight % of at least one tea polyphenol for a chewing gum containing at least one organic acid.